Johnson & Johnson mentioned late Thursday that preliminary knowledge exhibits its single-shot vaccine is efficient in opposition to the fast-spreading Delta variant of COVID-19 that was first found in India.
In an announcement, the New Jersey-based firm mentioned that its vaccine generated an immune response in opposition to the variant that lasted at the very least eight months. J&J added that its vaccine brought on extra antibody exercise in opposition to the Delta variant than in opposition to the Beta variant, which was first positioned in South Africa, although the dose labored in opposition to all so-called “variants of concern.”
The corporate mentioned the information got here from two small sub-studies that have been offshoots of its unique vaccine trial. Each research, which examined vaccine recipients’ blood, had been submitted for publication.
“As we speak’s newly introduced research reinforce the power of the Johnson & Johnson COVID-19 vaccine to assist defend the well being of individuals globally,” mentioned J&J Chief Scientific Officer Dr. Paul Stoffels in an announcement. “We imagine that our vaccine affords sturdy safety in opposition to COVID-19 and elicits neutralizing exercise in opposition to the Delta variant. This provides to the sturdy physique of scientific knowledge supporting our single-shot vaccine’s capacity to guard in opposition to a number of variants of concern.”
“Present knowledge for the eight months studied up to now present that the single-shot Johnson & Johnson COVID-19 vaccine generates a robust neutralizing antibody response that doesn’t wane; quite, we observe an enchancment over time,” added Dr. Mathai Mammen, the top of analysis and improvement for Johnson & Johnson’s pharmaceutical division. “As well as, we observe a persistent and notably sturdy, sturdy mobile immune response. With every new dataset, we construct on our strong basis of proof that our single-shot COVID-19 vaccine performs a vital function in ending the pandemic, which continues to evolve and pose new challenges to world well being.”
The announcement follows an announcement earlier this week by Moderna that its mRNA vaccine had produced antibodies in opposition to a number of coronavirus variants, together with the Delta pressure, in a lab research. A separate research printed in the journal Nature steered mRNA vaccines produced by Moderna and Pfizer may present “persistent” safety in opposition to COVID-19 for years — supplied the virus doesn’t mutate an excessive amount of past its present kinds.
On Wednesday, Facilities for Illness Management and Prevention (CDC) Director Dr. Rochelle Walensky mentioned totally vaccinated Individuals are “fairly shielded from the variants that now we have circulating right here in america” and reiterated that these folks don’t have to put on a masks.
That got here on the heels of a suggestion by Los Angeles County well being officers for folks to renew sporting masks in indoor public areas, no matter their vaccination standing, because of a rise in instances blamed on the variant.
Walensky additionally instructed NBC’s “As we speak” present that Individuals who obtained the J&J vaccine doubtless don’t want to return for a booster shot, an announcement supported by the preliminary knowledge introduced Thursday.
“We’ve got each cause to imagine, based mostly on how J&J is performing with different variants of concern – and that’s fairly effectively – and the way its sister vaccine, AstraZeneca, has carried out in opposition to the Delta variant in different nations … individuals are agreeing that they anticipate that the J&J will carry out effectively in opposition to the Delta variant, because it has up to now in opposition to different variants circulating in america,” she mentioned.